Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Receivables: 2017-2025

Historic Change in Receivables for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $7.4 million.

  • Puma Biotechnology's Change in Receivables fell 71.91% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.8 million, marking a year-over-year decrease of 184.27%. This contributed to the annual value of -$16.3 million for FY2024, which is 295.33% down from last year.
  • As of Q3 2025, Puma Biotechnology's Change in Receivables stood at $7.4 million, which was up 1,879.26% from $376,000 recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Change in Receivables peaked at $26.5 million during Q3 2024, and registered a low of -$23.1 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Receivables was $376,000 (2025), whereas its average is -$616,818.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 1,569.19% in 2021, then crashed by 992.20% in 2022.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Change in Receivables stood at $8.7 million in 2021, then surged by 41.17% to $12.3 million in 2022, then surged by 56.09% to $19.2 million in 2023, then plummeted by 219.76% to -$23.0 million in 2024, then tumbled by 71.91% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $376,000 for Q2 2025, and -$6.6 million during Q1 2025.